ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
After market 06:17:04 pm | |||
| 776.8 USD | -0.56% |
|
777 | +0.03% |
| May. 01 | Amgen investors await weight-loss drug data | RE |
| May. 01 | Danish Medicines Agency Says Type 2 Diabetes Patients Should Start Treatment With 'Cheaper' Drugs | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
2024-05-06
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
781.1
USD
Average target price
845.3
USD
Spread / Average Target
+8.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +33.25% | 704B | |
| +28.59% | 577B | |
| -3.55% | 348B | |
| +18.16% | 327B | |
| +4.36% | 288B | |
| +14.81% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -3.69% | 147B | |
| -5.59% | 145B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly's $14 Million Insulin Settlement Shelved Amid Unfavorable Ruling
